Back

MYC controls metastatic heterogeneity in pancreatic cancer

Maddipati, R.; Norgard, R.; Baslan, T.; Rathi, K.; Zhang, A.; Raman, P.; Pitarresi, J.; Wengyn, M.; Yamazoe, T.; Li, J.; Balli, D.; LaRiviere, M.; Folkert, I.; Millstein, I.; Bermeo, J.; Carpenter, E.; Lowe, S.; Iacobuzio-Donahue, C. A.; Notta, F.; Stanger, B.

2021-02-01 cancer biology
10.1101/2021.01.30.428641 bioRxiv
Show abstract

The degree of metastatic disease varies widely amongst cancer patients and impacts clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multi-fluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC) - a tumor type where most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of MYC and its downstream targets. Functional experiments showed that MYC promotes metastasis by recruiting tumor associated macrophages (TAMs), leading to greater bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically in metastatic patients. Collectively, these results implicate MYC activity as a major determinant of metastatic burden in advanced PDAC.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.